Le Registre des lobbyistes
| Objets | Détails | Catégories |
|---|---|---|
|
Budget, Développement économique, Marchés publics, Santé
|
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
|
Politique ou Programme
|
|
Développement économique, Commerce international
|
Canada-European Union Comprehensive Economic Trade Agreement with respect to strengthening Intellectual Property Protection provisions under the Patent Act and related regulations.
|
Proposition législative, Projet de loi ou résolution, Politique ou Programme, Règlement
|
|
Développement économique, Propriété intellectuelle, Commerce international
|
Canada-Europe Comprehensive Economic and Trade Agreement - Intellectual Property Provisions
|
Proposition législative, Projet de loi ou résolution, Règlement
|
|
Développement économique, Santé, Propriété intellectuelle
|
Canada’s Access to Medicines Regime (CAMR), certified under the Patent Act, which allows developing countries to access drugs at a lower cost, with regard to ensuring that Intellectual Property rights and anti-diversion mechanisms continue to be respected.
|
Politique ou Programme
|
|
Santé, Commerce international
|
Drug Re-importation - Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level re-importation legislation.
|
Règlement, Politique ou Programme
|
|
Développement économique, Santé
|
Engagement with federal officials regarding the Biomanufacturing & Life Sciences Strategy
|
Politique ou Programme
|
|
Développement économique, Santé, Recherche et développement
|
Engagement with the Government regarding the Strategic Innovation Fund
|
Subvention, Contribution ou autre avantage financier, Politique ou Programme
|
|
Santé
|
Engage the Government regarding the need for clear and efficient procurement processes for COVID-19 medical countermeasures, including COVID-19 therapeutics, to ensure access for Canadians.
|
Politique ou Programme
|
|
Santé
|
Engage with government to strengthen the Priority Review for Drug Submissions process.
|
Politique ou Programme
|
|
Développement économique, Santé
|
FedDev Ontario Advanced Manufacturing Fund - advancing manufacturing of innovative pharmaceutical products in southern Ontario
|
Politique ou Programme, Subvention, Contribution ou autre avantage financier
|
|
Santé
|
Food and Drugs Act and the bill formerly known as Bill C-51: An Act to amend the Food and Drugs Act and to make consequential amendments to other Acts. Specifically, with respect to the renewal of the drug approval process.
Advocacy to ensure that Canada's review and approval process is timely, safe, effective, competitive and consistent with other jurisdictions.
|
Proposition législative, Projet de loi ou résolution
|
|
Santé
|
Legislation, regulations, policies and programs concerning the federal government's response to COVID-19, including pandemic preparedness, pharmaceutical and vaccine supply-chain management, and general administration of justice.
|
Proposition législative, Projet de loi ou résolution, Politique ou Programme, Règlement
|
|
Santé
|
National Immunization Strategy.
Advocacy to seek continued investment in vaccines funding and an overall strategy for prevention of disease in Canada.
|
Politique ou Programme
|
|
Développement économique, Propriété intellectuelle
|
Patented Medicines (Notice of Compliance) Regulations which seek to balance the protection of Intellectual Property (IP) and patents with cost containment.
Advocacy to ensure that IP rights are respected and internationally competitive in order to promote Research and Development.
|
Règlement
|
|
Développement économique, Santé
|
Patented Medicines Review Board (PMPRB), certified under the Patent Act and whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB are consistent with the mandate assigned by Parliament.
|
Politique ou Programme
|
|
Santé
|
Policies and programs related to the health of new immigrants to Canada.
|
Politique ou Programme
|
|
Marchés publics, Santé
|
Public Services and Procurement Canada (PSPC) Integrity Framework - Clarifying the process for procurement of vaccines and possibly pharmaceuticals under the evolving procurement framework.
|
Politique ou Programme
|
|
Développement économique, Propriété intellectuelle, Sciences et technologies
|
Science and Technology (S&T) Strategy: Mobilizing Science and Technology to Canada's Advantage.
Advocacy for measures which will allow for commercialization in health care to occur and for Canada to remain competitive internationally on Intellectual Property and other fronts.
|
Politique ou Programme
|
|
Santé
|
The Common Drug Review (CDR) process for reviewing new drugs and providing listing recommendations to publicly funded drug benefit plans in Canada.
Ensuring the access needs of Canadian patients are met by advocating on activities undertaken in the context of the CDR.
|
Politique ou Programme
|
|
Santé
|
The National Pharmaceutical Strategy (NPS) as agreed by First Ministers in 2004.
Advocacy for ways to increase access to medicines and vaccines for Canadian patients.
|
Politique ou Programme
|
GLAXOSMITHKLINE IS ONE OF CANADA'S LARGEST RESEARCH-BASED PHARMACEUTICAL COMPANIES. GLAXOSMITHKLILNE OPERATES FOUR MAIN FACILITIES IN CANADA, INCLUDING ITS HEAD OFFICE AND MANUFACTURING OPERATIONS IN MISSISSAUGA, AND ITS BUREAU D'AFFAURES DU QUEBEC IN MONTREAL. IN TOTAL GLAXOSMITHKLINE EMPLOYS APPROXIMATELY 1,800 PEOPLE ACROSS THE COUNTRY. GSK IS A LEADER IN MANY IMPORTANT THERAPEUTIC AREAS, INCLUDING RESPIRATORY, CENTRAL NERVOUS SYSTEM, ANTI-INFECTIVES AND GASTRO INTESTINAL/METABOLIC. GLAXOSMITHKLINE INVESTS MORE THAN $100 MILLION IN RESEARCH & DEVELOPMENT IN CANADA EACH YEAR. GLAXOSMITHKLINE'S $120 MILLION MANUFACTURING OPERATIONS PRODUCE MORE THAN 100 MEDICINES AND 20 MILLION UNITS ANNUALLY.
Sridhar Venkatesh, General Manager and President
Adresse :
100 Milverton Drive, Suite 800
Mississauga, ON L5R 4H1
Canada
Numéro de téléphone :
905-819-3000